Is 2561.HK overvalued or undervalued?

2561.HK currently has a P/E ratio of -7.17. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy VISEN Pharmaceuticals stock?

VISEN Pharmaceuticals trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2561.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2561.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2561.HK to protect their purchasing power. Because 2561.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2561.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2561.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2561.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2561.HK

VISEN Pharmaceuticals

HK$18.53-HK$0.28-1.49%

HKSE / HKD

Market cap

HK$2.0B

P/E

-7.2

EPS (TTM)

HK$-0.31

Dividend yield

0.00%

Beta

0.87

1Y return

-56.60%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$02021

$02022

$-235,0792023

$380,3382024

$22,9782025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.26Low
Current ratio4.00
Cash ratio2.38
Net margin-1,173.9%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2561.HK-7.2
Healthcare sector median26.8
S&P 50022.0

Trades about 127% below its sector, cheaper than its peers on earnings.

Ratios

PEG-19.76
Price to book2.58
EPS (TTM)HK$-0.31
Payout ratio0%
FCF yield-14.74%

Range & risk

HK$18.50HK$44.06

Trading in the lower third of its 52-week band

Beta0.87

Profile

What VISEN Pharmaceuticals actually does

VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.

CEO

An-bang Lu

Employees

Headquarters

Suzhou, JS

Founded

2025-03-21

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2561.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2561.HK has a beta of 0.87, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

VISEN Pharmaceuticals